Dexmedetomidine Enhancing the Recovery After Cardiac Surgery
Key facts
- Who runs it
- Benha University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 75 people enrolled
- Started
- 30 Aug 2024
- Ended
- 31 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexmedetomidine
- Fentanyl
- Lidocain
- Record updated
- 2 April 2025
Who can take part
- Age
- 40 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients of American Society of Anesthesiologists Classification (ASA) grade II-III
- Patients who were planned to have Coronary Artery Bypass Graft (CABG)
- Patients were free of exclusion criteria
Who cannot take part
- Patients with preoperative high risk for getting Post Operative Delirium or sleep disorders,
- Patients with uncontrolled diabetes mellitus, coagulopathy, or history of uncompensated renal or hepatic diseases
- Patients with heart failure, left ventricle ejection fraction of <25%,
- Patients with American Society of Anesthesiologists Classification (ASA) grade>III
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Enhanced Recovery After Surgery (ERAS) aims to facilitate a quicker and smoother recovery period following surgical procedures. The implementation of these protocols may lead to patients returning to their daily activities sooner, experiencing greater satisfaction with their care, and potentially encountering fewer complications, ultimately contributing to shorter hospital stays. However, a common challenge in the postoperative phase is postoperative delirium(POD). This complication can lead to both immediate and long-term cognitive impairments, negatively impact overall health outcomes, and increase the financial burden on the healthcare system. Interestingly, dexmedetomidine, known as DXM, is a medication that selectively targets certain receptors in the brain and offers sedative properties with minimal impact on breathing. This characteristic is noteworthy because it may help regulate sleep patterns and support the preservation of cognitive function during the recovery period.
The 2 groups in the trial
- Group DExisting treatment, for comparison
Treatment: Dexmedetomidine and Lidocain
- Group FExisting treatment, for comparison
Treatment: Fentanyl
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dexmedetomidine-based Enhanced Recovery After Cardiac Surgery Improves Outcome Regarding Analgesia, Sleep Disorders, and Postoperative Delirium
- Record updated
- 2 April 2025